Register
Login

Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

02:37 mins

Gemmy Cheung, EURETINA 2022: New Imaging Insights in Central Serous Chorioretinopathy Part 2

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Oct 18th 2022

In this touchOPHTHALMOLOGY interview, Prof. Gemmy Cheung (Duke-NUS Medical School, National University of Singapore, Singapore) discussed how the imaging techniques that have been used for the classification and diagnosis of central serous chorioretinopathy have been changing.

‘New imaging insights in CSC’ was presented at EURETINA 2022, 1–4 September 2022 

  1. How have advances in imaging techniques enhanced our understanding of the pathophysiology of central serous chorioretinopathy (CSC)? (00:13)
  2. How have these advances impacted on our management of CSC? (01:45)

Disclosure: Gemmy Cheung has nothing to disclose in relation to this video.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.

Filmed as a highlight of EURETINA 2022.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup